Law360 (February 5, 2019, 6:49 PM EST) -- A Massachusetts federal judge on Tuesday denied GlaxoSmithKline a quick win in multidistrict litigation claiming its anti-nausea drug Zofran led to birth defects, saying GSK has not proven the U.S. Food and Drug Administration would have rejected a stricter warning label.
U.S. District Judge F. Dennis Saylor IV denied the drugmaker’s motion for summary judgment, saying there remain questions of fact about whether GSK fully disclosed material data about Zofran to the FDA and whether the allegedly withheld data would have swayed the agency’s decision on the drug’s warning label.
“In other words, GSK must essentially show that the FDA either...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!